Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALAOTCMKTS:GWHPNASDAQ:SCPSOTCMKTS:SPHS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALACalithera Biosciences$0.00-95.0%$0.00$0.00▼$0.05N/A-2.5616,374 shs6,448 shsGWHPGlobal WholeHealth Partners$0.00$0.00▼$0.00$10KN/AN/AN/ASCPSScopus BioPharma$0.01+3,233.3%$0.00$0.00▼$0.01$421K-0.232,238 shs10,922 shsSPHSSophiris Bio$0.00$0.00▼$0.05$4K1.94N/AN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALACalithera Biosciences-95.00%-95.00%-83.33%-83.33%-99.20%GWHPGlobal WholeHealth Partners0.00%0.00%0.00%0.00%0.00%SCPSScopus BioPharma+3,233.33%+3,233.33%+3,233.33%+3,233.33%+4,900.00%SPHSSophiris Bio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALACalithera Biosciences0.5747 of 5 stars0.01.00.04.50.60.00.0GWHPGlobal WholeHealth PartnersN/AN/AN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALACalithera Biosciences 0.00N/AN/AN/AGWHPGlobal WholeHealth Partners 0.00N/AN/AN/ASCPSScopus BioPharma 0.00N/AN/AN/ASPHSSophiris Bio 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALACalithera BiosciencesN/AN/AN/AN/AN/AN/AGWHPGlobal WholeHealth Partners$10K0.00N/AN/AN/ANaNSCPSScopus BioPharmaN/AN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/AGWHPGlobal WholeHealth Partners-$5.16MN/A0.00N/AN/AN/AN/AN/AN/ASCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/AN/AN/ASPHSSophiris BioN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALACalithera BiosciencesN/AN/AN/AN/AN/AGWHPGlobal WholeHealth PartnersN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/ASPHSSophiris BioN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALACalithera BiosciencesN/AGWHPGlobal WholeHealth PartnersN/ASCPSScopus BioPharmaN/ASPHSSophiris BioN/AInsider OwnershipCompanyInsider OwnershipCALACalithera Biosciences6.60%GWHPGlobal WholeHealth Partners10.30%SCPSScopus BioPharma5.10%SPHSSophiris Bio4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableGWHPGlobal WholeHealth Partners6143.88 million129.07 millionNot OptionableSCPSScopus BioPharma942.08 million39.94 millionNot OptionableSPHSSophiris Bio635.55 millionN/ANot OptionableSPHS, SCPS, CALA, and GWHP HeadlinesRecent News About These CompaniesWisr AI Systems Inc. Announces Closing of AmalgamationDecember 20, 2024 | newsfilecorp.comBioinspired materials articles from across Nature PortfolioNovember 13, 2024 | nature.comRyan Garcia: Biography, record, fights and moreDecember 3, 2023 | espn.comBest Louisiana High SchoolsOctober 13, 2023 | usnews.comSouth Portland High sends students home after morning lockdownOctober 9, 2023 | pressherald.comBLTE - Belite Bio, IncJuly 20, 2023 | finance.yahoo.comTycho Brahe: Colorful life, accomplishments and bizarre deathJune 23, 2023 | space.comBio-Reference LaboratoriesJune 12, 2023 | forbes.comCommunity News – Calling all Red Riots; South Portland H.S. Alumni Network launchedApril 15, 2023 | pressherald.comUkraine conflict: Germany orders 10 PzH 2000 SPHs to replace those sent to KyivApril 2, 2023 | janes.comSophiris Bio Inc. Registered Sh (BFF1.SG)March 20, 2023 | finance.yahoo.com18 ways you didn't know you could use bio-oil, plus the celebs who swear by itMarch 18, 2023 | womenshealthmag.comSPHS Indoor Track Wins Girls Blue Division at GMC ChampionshipsJanuary 25, 2023 | msn.comSPHS Weekly Sports Recap: All Sports Notch Big WinsJanuary 17, 2023 | msn.comPennsylvania Gov.-elect Josh Shapiro biographyJanuary 14, 2023 | wgal.comNarendra Modi Biography: Childhood, Family, Education, Political Life, Net Worth & Key FactsSeptember 17, 2022 | jagranjosh.comWeapons newsSeptember 9, 2022 | janes.comNew MarketBeat Followers Over TimeSPHS, SCPS, CALA, and GWHP Company DescriptionsCalithera Biosciences NASDAQ:CALA$0.0001 0.00 (-95.00%) As of 06/16/2025 02:12 PM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Global WholeHealth Partners OTCMKTS:GWHPGlobal WholeHealth Partners Corporation develops and markets various in-vitro diagnostic (IVD) test kits in the United States. The company offers approximately 125 diagnostic tests kits for over-the-counter or consumer-use, as well as for point-of-care, which includes hospitals, physicians' offices, and medical clinics. It provides tests for various diseases, such as Ebola, zika, dengue, malaria, influenza, tuberculosis, coronaviruses, yellow fever, and other epidemic and vector-borne diseases. The company was incorporated in 2013 and is based in Newport Beach, California.Scopus BioPharma NASDAQ:SCPS$0.01 +0.01 (+3,233.33%) As of 06/16/2025 12:41 PM EasternScopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Sophiris Bio OTCMKTS:SPHSSophiris Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products for the treatment of urological diseases. The company was founded by James L. Heppell in May 2003 and is headquartered in La Jolla, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
